Small Cap Movers

Geron receives $1.5M milestone payment for FDA risk assessment

SMALLCAP MARKETPLACE
Jennifer Schonberger | Apr 15, 2008 9:23am EDT | Comment
Rating: Unrated [rate it]

Geron Corp. (Nasdaq:GERN), which develops biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, said this morning that it received a milestone payment of $1.5 million from Exeter Life Sciences, Inc. for the final “risk assessment” released by the U.S. Food and Drug Administration addressing food products made from cloned animals or their progeny.  

Shares gained 4%, or $0.19, to $5.37 ahead of the opening bell. For detailed price information and recent news stories about Geron, click GERN.

Jennifer Schonberger

About the Author
Reporter Jennifer Schonberger is based in SmallCapInvestor.com's Washington, D.C. bureau. Read More


Rate This Article
Rate This Article:
(click a star)
PoorFairGoodBest
Comment on This Article

Enter comment:

 Free registration required

GERN Fast Facts:

insight and analysis from our partnersGrowth ReportRising Start StocksTop Stock InsightsBig Idea Investor
Advertise | Contact Us | About Us | Contributors | Become a Contributor | Jobs | Press Releases